Crohn's disease therapeutic dietary intervention (CD-TDI): study protocol for a randomised controlled trial

Maitreyi Raman, Christopher Ma, Lorian M Taylor, Levinus A Dieleman, Georgios V Gkoutos, Jeff K Vallance, Kathy D McCoy, Ian Lewis, Humberto Jijon, Derek M McKay, David M Mutch, Herman W Barkema, Deanna Gibson, Marcus Rauch, Subrata Ghosh, Maitreyi Raman, Christopher Ma, Lorian M Taylor, Levinus A Dieleman, Georgios V Gkoutos, Jeff K Vallance, Kathy D McCoy, Ian Lewis, Humberto Jijon, Derek M McKay, David M Mutch, Herman W Barkema, Deanna Gibson, Marcus Rauch, Subrata Ghosh

Abstract

Introduction: Dietary patterns that might induce remission in patients with active Crohn's disease (CD) are of interest to patients, but studies are limited in the published literature. We aim to explore the efficacy of the CD therapeutic dietary intervention (CD-TDI), a novel dietary approach developed from best practices and current evidence, to induce clinical and biomarker remission in adult patients with active CD.

Methods and analysis: This study is a 13-week, multicentre, randomised controlled trial in patients with mild-to-moderate active CD at baseline. One hundred and two patients will be block randomised, by sex, 2:1 to the intervention (CD-TDI) or conventional management. Coprimary outcomes are clinical and biomarker remission, defined as a Harvey Bradshaw Index of <5 and a faecal calprotectin of <250 µg/g, respectively.Secondary outcomes include gut microbiota diversity and composition, faecal short-chain fatty acids, regulatory macrophage function, serum and faecal metabolomics, C reactive protein, peripheral blood mononuclear cell gene expression profiles, quality of life, sedentary time and physical activity at 7 and/or 13 weeks. Predictive models of clinical response to a CD-TDI will be investigated.

Ethics and dissemination: The research protocol was approved by the Conjoint Health Research Ethics Board at the University of Calgary (REB19-0402) and the Health Research Ethics Board-Biomedical Panel at the University of Alberta (Pro00090772). Study findings will be presented at national and international conferences, submitted for publication in abstracts and manuscripts, shared on social media and disseminated through patient-education materials.

Trial registration number: NCT04596566.

Keywords: Crohn's disease; clinical trials; diet; inflammatory bowel disease.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Study design.
Figure 2
Figure 2
Study timelines.

References

    1. Dignass A, Lindsay JO, Sturm A, et al. . Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012;6:991–1030. 10.1016/j.crohns.2012.09.002
    1. Jowett SL, Seal CJ, Phillips E, et al. . Dietary beliefs of people with ulcerative colitis and their effect on relapse and nutrient intake. Clin Nutr 2004;23:161–70. 10.1016/S0261-5614(03)00132-8
    1. Roda G, Jharap B, Neeraj N, et al. . Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol 2016;7:e135. 10.1038/ctg.2015.63
    1. Singh S, Fumery M, Sandborn WJ, et al. . Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease. Aliment Pharmacol Ther 2018;48:394–409. 10.1111/apt.14852
    1. Opstelten JL, de Vries JHM, Wools A, et al. . Dietary intake of patients with inflammatory bowel disease: a comparison with individuals from a general population and associations with relapse. Clin Nutr 2019;38:1892–8. 10.1016/j.clnu.2018.06.983
    1. Hou JK, Abraham B, El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol 2011;106:563–73. 10.1038/ajg.2011.44
    1. Ananthakrishnan AN, Khalili H, Konijeti GG, et al. . A prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis. Gastroenterology 2013;145:970–7. 10.1053/j.gastro.2013.07.050
    1. Opstelten JL, Leenders M, Dik VK, et al. . Dairy products, dietary calcium, and risk of inflammatory bowel disease. Inflamm Bowel Dis 2016;22:1403–11. 10.1097/MIB.0000000000000798
    1. Albenberg LG, Wu GD,. Diet and the intestinal microbiome: associations, functions, and implications for health and disease. Gastroenterology 2014;146:1564–72. 10.1053/j.gastro.2014.01.058
    1. Palm NW, de Zoete MR, Cullen TW, et al. . Immunoglobulin A coating identifies colitogenic bacteria in inflammatory bowel disease. Cell 2014;158:1000–10. 10.1016/j.cell.2014.08.006
    1. Alam A, Neish A. Role of gut microbiota in intestinal wound healing and barrier function. Tissue Barriers 2018;6:1539595. 10.1080/21688370.2018.1539595
    1. Limdi JK, Aggarwal D, McLaughlin JT. Dietary practices and beliefs in patients with inflammatory bowel disease. Inflamm Bowel Dis 2016;22:164–70. 10.1097/MIB.0000000000000585
    1. Zallot C, Quilliot D, Chevaux J-B, et al. . Dietary beliefs and behavior among inflammatory bowel disease patients. Inflamm Bowel Dis 2013;19:66–72. 10.1002/ibd.22965
    1. Cohen AB, Lee D, Long MD, et al. . Dietary patterns and self-reported associations of diet with symptoms of inflammatory bowel disease. Dig Dis Sci 2013;58:1322–8. 10.1007/s10620-012-2373-3
    1. Levine A, Wine E, Assa A, et al. . Crohn's disease exclusion diet plus partial enteral nutrition induces sustained remission in a randomized controlled trial. Gastroenterology 2019;157:440–50. 10.1053/j.gastro.2019.04.021
    1. Lewis JD, Sandler RS, Brotherton C, et al. . A randomized trial comparing the specific carbohydrate diet to a Mediterranean diet in adults with Crohn's disease. Gastroenterology 2021;161:837–52. 10.1053/j.gastro.2021.05.047
    1. Svolos V, Hansen R, Nichols B, et al. . Treatment of active Crohn's disease with an ordinary food-based diet that replicates exclusive enteral nutrition. Gastroenterology 2019;156:1354–67. 10.1053/j.gastro.2018.12.002
    1. Levine A, Scaldaferri F, Sarbagili Shabat C, et al. . OP01 comparison of fecal transplantation, fecal transplantation with the novel UC diet or the UC diet alone for refractory mild to moderate active ulcerative colitis: the craft UC randomized controlled trial. J Crohns Colitis 2021;15:S001. 10.1093/ecco-jcc/jjab075.000
    1. Zhang Z, Taylor L, Shommu N, et al. . A diversified dietary pattern is associated with a balanced gut microbial composition of Faecalibacterium and Escherichia/Shigella in patients with Crohn's disease in remission. J Crohns Colitis 2020;14:1547–57. 10.1093/ecco-jcc/jjaa084
    1. Naqvi SA, Taylor LM, Panaccione R, et al. . Dietary patterns, food groups and nutrients in Crohn's disease: associations with gut and systemic inflammation. Sci Rep 2021;11:1674. 10.1038/s41598-020-80924-8
    1. Bhattacharyya S, Shumard T, Xie H, et al. . A randomized trial of the effects of the no-carrageenan diet on ulcerative colitis disease activity. Nutr Healthy Aging 2017;4:181–92. 10.3233/NHA-170023
    1. Chassaing B, Koren O, Goodrich JK, et al. . Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature 2015;519:92–6. 10.1038/nature14232
    1. Levine A, Rhodes JM, Lindsay JO, et al. . Dietary guidance from the International organization for the study of inflammatory bowel diseases. Clin Gastroenterol Hepatol 2020;18:1381–92. 10.1016/j.cgh.2020.01.046
    1. Prestwich A, Kellar I, Parker R, et al. . How can self-efficacy be increased? meta-analysis of dietary interventions. Health Psychol Rev 2014;8:270–85. 10.1080/17437199.2013.813729
    1. Ottery FD. Definition of standardized nutritional assessment and interventional pathways in oncology. Nutrition 1996;12:S15–19. 10.1016/0899-9007(95)00067-4
    1. Spitzer RL, Kroenke K, Williams JBW, et al. . A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006;166:1092–7. 10.1001/archinte.166.10.1092
    1. Conway JM, Ingwersen LA, Vinyard BT, et al. . Effectiveness of the US department of agriculture 5-step multiple-pass method in assessing food intake in obese and nonobese women. Am J Clin Nutr 2003;77:1171–8. 10.1093/ajcn/77.5.1171
    1. Conway JM, Ingwersen LA, Moshfegh AJ. Accuracy of dietary recall using the USDA five-step multiple-pass method in men: an observational validation study. J Am Diet Assoc 2004;104:595–603. 10.1016/j.jada.2004.01.007
    1. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980;1:514. 10.1016/s0140-6736(80)92767-1
    1. Jones J, Loftus EV, Panaccione R, et al. . Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008;6:1218–24. 10.1016/j.cgh.2008.06.010
    1. Vermeire S, Van Assche G, Rutgeerts P. C-Reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004;10:661–5. 10.1097/00054725-200409000-00026
    1. Mager LF, Burkhard R, Pett N, et al. . Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science 2020;369:1481–9. 10.1126/science.abc3421
    1. Wyss M, Brown K, Thomson CA, et al. . Using Precisely Defined in vivo Microbiotas to Understand Microbial Regulation of IgE. Front Immunol 2019;10:3107. 10.3389/fimmu.2019.03107
    1. Jayme TS, Leung G, Wang A, et al. . Human interleukin-4-treated regulatory macrophages promote epithelial wound healing and reduce colitis in a mouse model. Sci Adv 2020;6:eaba4376. 10.1126/sciadv.aba4376
    1. Prescott D, McKay DM. Aspirin-triggered lipoxin enhances macrophage phagocytosis of bacteria while inhibiting inflammatory cytokine production. Am J Physiol Gastrointest Liver Physiol 2011;301:G487–97. 10.1152/ajpgi.00042.2011
    1. Mancini NL, Rajeev S, Jayme TS, et al. . Crohn's disease pathobiont adherent-invasive E coli disrupts epithelial mitochondrial networks with implications for gut permeability. Cell Mol Gastroenterol Hepatol 2021;11:551–71. 10.1016/j.jcmgh.2020.09.013
    1. Ye J, Haskey N, Dadlani H, et al. . Deletion of mucin 2 induces colitis with concomitant metabolic abnormalities in mice. Am J Physiol Gastrointest Liver Physiol 2021;320:G791–803. 10.1152/ajpgi.00277.2020
    1. Ware J, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220–33. 10.1097/00005650-199603000-00003
    1. Colombel J-F, Panaccione R, Bossuyt P, et al. . Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet 2017;390:2779–89. 10.1016/S0140-6736(17)32641-7
    1. Liu M, Wei L, Zhang J. Review of guidelines and literature for handling missing data in longitudinal clinical trials with a case study. Pharm Stat 2006;5:7–18. 10.1002/pst.189
    1. Hedeker D, Gibbons RD. Application of random-effects pattern-mixture models for missing data in longitudinal studies. Psychol Methods 1997;2:64–78. 10.1037/1082-989X.2.1.64
    1. Little RJ, D'Agostino R, Cohen ML, et al. . The prevention and treatment of missing data in clinical trials. N Engl J Med 2012;367:1355–60. 10.1056/NEJMsr1203730
    1. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for illumina sequence data. Bioinformatics 2014;30:2114–20. 10.1093/bioinformatics/btu170
    1. WestGrid and Comupte Canada Calcul Canada . BMTagger [Website], 2020. Available: [Accessed 25 Oct 2021].
    1. Beghini F, McIver LJ, Blanco-Míguez A, et al. . Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3. Elife 2021;10:e65088. 10.7554/eLife.65088
    1. Pimentel H, Bray NL, Puente S, et al. . Differential analysis of RNA-Seq incorporating quantification uncertainty. Nat Methods 2017;14:687–90. 10.1038/nmeth.4324

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren